4//SEC Filing
Aunins John G. 4
Accession 0000899243-18-017017
CIK 0001609809other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 4:43 PM ET
Size
5.3 KB
Accession
0000899243-18-017017
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Sale
Common Stock
2018-06-15$8.57/sh−14,279$122,325→ 170,206 total
Footnotes (2)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 15, 2018.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $8.39 to $8.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001643756
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 4:43 PM ET
- Size
- 5.3 KB